Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company pioneering receptor-targeted therapies for metabolic and endocrine disorders. This page serves as the definitive source for all official updates and analysis-worthy developments related to the company’s innovative pipeline.
Investors and industry observers will find timely, verified information spanning clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases on key programs like the thyroid receptor agonist VK2809 for NASH, dual GLP-1/GIP agonist VK2735 for obesity, and rare disease candidate VK0214 – all developed through Viking’s receptor-specific therapeutic approach.
Content is organized to highlight material events including Phase 1-3 trial results, FDA communications, patent developments, and peer-reviewed research publications. Each update is contextualized within Viking’s broader mission to address unmet needs in metabolic health through precision pharmacology.
For consistent monitoring of Viking’s advancements in liver disease and endocrine disorder treatments, bookmark this page and revisit for authoritative reporting on trial data disclosures and corporate announcements. All content adheres to strict journalistic standards for accuracy and regulatory compliance.
Viking Therapeutics, Inc. (VKTX) announced a clinical hold by the FDA on its Phase 1b trial of VK0214 for X-linked adrenoleukodystrophy (X-ALD). The FDA requires an additional preclinical study, specifically a rodent genotoxicity study, before the trial can continue. This hold is not based on any findings from prior studies. The company expects to submit the requested data in Q2 2022, aiming to resume dosing later this year. VK0214 has previously shown promising safety and efficacy results, including reductions in LDL cholesterol and triglycerides.
Viking Therapeutics (NASDAQ: VKTX) announced the initiation of a Phase 1 clinical trial for VK2735, a novel dual agonist targeting GLP-1 and GIP receptors, aimed at treating metabolic disorders. This double-blind, placebo-controlled study will assess safety, tolerability, and pharmacokinetics in healthy adults, with exploratory assessments of body weight and liver fat changes. VK2735 is expected to enhance therapeutic effects compared to existing treatments like semaglutide. The trial marks a significant milestone for Viking, which aims to report topline results later in the year.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available online once the conference begins, with a webcast accessible via Viking's website. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders, including its lead candidates VK2809 and VK0214, which are in advanced stages of clinical trials.
Viking Therapeutics (NASDAQ: VKTX) will present at the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. CEO Brian Lian, Ph.D., is scheduled to speak on November 16 from 4:00 to 4:30 p.m. Eastern. Interested parties can access the presentation via the company's website, with a replay available post-conference. Viking focuses on therapies for metabolic and endocrine disorders, including VK2809, currently in a Phase 2b study for non-alcoholic steatohepatitis.
Viking Therapeutics (VKTX) reported its Q3 2021 financial results with a net loss of $13.2 million ($0.17 per share), compared to a loss of $9.3 million ($0.13 per share) in Q3 2020. The increase in loss was attributed to rising research and development expenses, now totaling $10.8 million, primarily for clinical studies. Viking is advancing its clinical pipeline, including ongoing Phase 2b VOYAGE trial for VK2809 in NASH and Phase 1b trial for VK0214 in X-ALD. The company ended Q3 with $216 million in cash, positioning it well for future developments.
Viking Therapeutics (NASDAQ: VKTX) presented preclinical data on dual GLP-1/GIP agonists at ObesityWeek 2021. The findings demonstrate significant weight loss and metabolic improvements in diet-induced obese mice, with weight reductions of up to 28%, and enhanced glucose and insulin responses compared to vehicle and semaglutide. The study results support the efficacy of dual agonists and provide a foundation for a forthcoming Phase 1 trial of a lead candidate. CEO Brian Lian emphasized the potential of these compounds in advancing treatment for metabolic disorders.
Viking Therapeutics (VKTX), a clinical-stage biopharmaceutical firm, will announce its third-quarter 2021 financial results on November 3, 2021, after market close. A conference call to discuss these results will follow at 4:30 p.m. ET. The company is developing oral therapies for metabolic and endocrine disorders, including VK2809, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH). VK2809 has shown efficacy in reducing LDL-C and liver fat in prior studies. The firm holds exclusive rights to five therapeutic programs from Ligand Pharmaceuticals.
Viking Therapeutics (NASDAQ: VKTX) announced the presentation of promising preclinical data on novel dual agonists targeting GLP-1 and GIP receptors at ObesityWeek 2021, occurring from November 1-5, 2021. Results from studies in diet-induced obese mice highlight significant weight loss and improved metabolic profiles. The poster presentations will be led by Kader Yagiz, Ph.D. This research could enhance Viking's pipeline of therapies for metabolic and endocrine disorders, further supporting its clinical programs, including VK2809 for NASH and fibrosis.
Viking Therapeutics (NASDAQ: VKTX) will have CEO Brian Lian, Ph.D., present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021. The virtual presentation is scheduled for 11:00 – 11:20 a.m. Eastern. Viking is focused on developing innovative therapies for metabolic and endocrine disorders, including VK2809, a selective thyroid hormone receptor beta agonist currently in Phase 2b for NASH. The company is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD).
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in four upcoming investor conferences. The events include Citi's 16th Annual Biopharma Virtual Conference (Sept 8-10), H.C. Wainwright's 23rd Annual Global Investment Conference (Sept 13-15), Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Sept 20-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept 27-30). Presentations will be available online, and webcasts will follow. Viking focuses on innovative therapies for metabolic disorders, with key programs including VK2809 and VK0214 currently in clinical trials.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
